GSK plc · LSE:GSK
Dr Hal Barron bought 2,466 GSK plc shares (PDMR dealing notification, UK MAR art. 19)
Traded Nov 13, 2026 · Filed Nov 17, 2026
On Nov 13, 2026, Dr Hal Barron (Non-Executive Director) bought 2,466 GSK plc shares at US$50.45 for US$124K. Filed Nov 17, 2026 (PDMR dealing notification, UK MAR art. 19).
- Bought
- 2,466 shares
- Price
- US$50.45
- Value
- US$124K
- Role
- Non-Executive Director
The filing in full
RNS Number : 5194D
GSK PLC
17 November 2026
GSK plc(the‘Company’)
Transaction notification
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
|---|---|---|---|---|---|
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2\. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares (‘ADS’)ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $50.4500 | 2,259.160 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-11-13 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
|---|---|---|---|---|---|
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2\. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares (‘ADS’)ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of notional ADS within Mr Ford’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $50.4500 | 53.408 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-11-13 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
|---|---|---|---|---|---|
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2\. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares (‘ADS’)ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $50.4500 | 81.902 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-11-13 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them (‘PCA’) | ||||
|---|---|---|---|---|---|
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2\. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares (‘ADS’)ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Acquisition of ADS within Dr Barron’s GSK 401(k) plan account following the reinvestment of dividends | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $50.4500 | 72 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-11-13 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [\[email protected\]](https://6ix-events-pro.s3.us-east-1.amazonaws.com/cdn-cgi/l/email-protection#c5b7abb685a9b6a0a2eba6aaa8) or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFAFFWEMSEDF
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | American Depositary Shares (‘ADS’) | Buy | 2,259 | US$50.45 | ||
| Nov 13, 2026 | American Depositary Shares (‘ADS’) | Buy | 53 | US$50.45 | ||
| Nov 13, 2026 | American Depositary Shares (‘ADS’) | Buy | 82 | US$50.45 | ||
| Nov 13, 2026 | American Depositary Shares (‘ADS’) | Buy | 72 | US$50.45 |
Source
Download original · View original at FCA
Related
- GSK plc
- Dr Hal Barron
- GSK plc shareholders
- PDMR dealing notification (UK MAR art. 19) · Luke Miels · Oct 13, 2026
- PDMR dealing notification (UK MAR art. 19) · Lynn Baxter · Nov 12, 2026
- PDMR dealing notification (UK MAR art. 19) · Maya Martinez-Davis · Oct 26, 2026
- PDMR dealing notification (UK MAR art. 19) · James Ford · Oct 15, 2026
- PDMR dealing notification (UK MAR art. 19) · Luke Miels · Oct 14, 2026
- PDMR dealing notification (UK MAR art. 19) · Luke Miels · Oct 12, 2026